JP2024521401A - 神経細胞リプログラミングのための方法及び組成物 - Google Patents

神経細胞リプログラミングのための方法及び組成物 Download PDF

Info

Publication number
JP2024521401A
JP2024521401A JP2023575711A JP2023575711A JP2024521401A JP 2024521401 A JP2024521401 A JP 2024521401A JP 2023575711 A JP2023575711 A JP 2023575711A JP 2023575711 A JP2023575711 A JP 2023575711A JP 2024521401 A JP2024521401 A JP 2024521401A
Authority
JP
Japan
Prior art keywords
ascl1
transcription factor
mutant
bhlh
bhlh transcription
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575711A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521401A5 (https=
Inventor
スチャーマンズ，キャロル
マクローリン，ジョアン
マーズヘッド，シンディー
パク，ユンジェ
ケタリ，ターラン
ヴァサン，ラクシュミー
ファイズ，マリアム
エンバー，トム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toronto
Original Assignee
University of Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toronto filed Critical University of Toronto
Publication of JP2024521401A publication Critical patent/JP2024521401A/ja
Publication of JP2024521401A5 publication Critical patent/JP2024521401A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023575711A 2021-06-09 2022-06-09 神経細胞リプログラミングのための方法及び組成物 Pending JP2024521401A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208627P 2021-06-09 2021-06-09
US63/208,627 2021-06-09
PCT/CA2022/050923 WO2022256933A1 (en) 2021-06-09 2022-06-09 Method and compositions for neuronal reprogramming

Publications (2)

Publication Number Publication Date
JP2024521401A true JP2024521401A (ja) 2024-05-31
JP2024521401A5 JP2024521401A5 (https=) 2025-06-16

Family

ID=84424544

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575711A Pending JP2024521401A (ja) 2021-06-09 2022-06-09 神経細胞リプログラミングのための方法及び組成物

Country Status (11)

Country Link
US (1) US20250282837A1 (https=)
EP (1) EP4352085A4 (https=)
JP (1) JP2024521401A (https=)
KR (1) KR20240032021A (https=)
CN (1) CN117881692A (https=)
AU (1) AU2022288230A1 (https=)
BR (1) BR112023025888A2 (https=)
CA (1) CA3222129A1 (https=)
IL (1) IL309190A (https=)
MX (1) MX2023014769A (https=)
WO (1) WO2022256933A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220084391A (ko) * 2019-10-21 2022-06-21 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 분기 형태들 합성
CN115670390B (zh) * 2022-12-30 2023-04-07 广东工业大学 一种帕金森病轴向症状严重程度表征方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037527A1 (en) * 2012-09-07 2014-03-13 Cambridge Enterprise Limited Maturation of mammalian cells by modulation of protein phosphorylation

Also Published As

Publication number Publication date
IL309190A (en) 2024-02-01
AU2022288230A1 (en) 2023-12-21
MX2023014769A (es) 2024-01-30
EP4352085A4 (en) 2025-07-23
KR20240032021A (ko) 2024-03-08
CN117881692A (zh) 2024-04-12
US20250282837A1 (en) 2025-09-11
EP4352085A1 (en) 2024-04-17
CA3222129A1 (en) 2022-12-15
WO2022256933A1 (en) 2022-12-15
BR112023025888A2 (pt) 2024-02-27

Similar Documents

Publication Publication Date Title
Tincer et al. Neural stem/progenitor cells in Alzheimer’s disease
Zhang et al. Identifying local and descending inputs for primary sensory neurons
Loera‐Valencia et al. Targeting Alzheimer's disease with gene and cell therapies
Furman et al. Blockade of astrocytic calcineurin/NFAT signaling helps to normalize hippocampal synaptic function and plasticity in a rat model of traumatic brain injury
Bouvier et al. The multifaceted neurotoxicity of astrocytes in ageing and age-related neurodegenerative diseases: a translational perspective
Accornero et al. Myofiber-specific inhibition of TGFβ signaling protects skeletal muscle from injury and dystrophic disease in mice
Hastings et al. Therapeutic potential of astrocyte transplantation
Jeong et al. Extracellular Vesicles Released from Neprilysin Gene‐Modified Human Umbilical Cord‐Derived Mesenchymal Stem Cell Enhance Therapeutic Effects in an Alzheimer’s Disease Animal Model
JP2013081480A (ja) 標的化された細胞死
Ghazale et al. Ascl1 phospho-site mutations enhance neuronal conversion of adult cortical astrocytes in vivo
JP2010531638A5 (https=)
Gupta et al. Human stem cell‐derived astrocytes and their application to studying N rf2‐mediated neuroprotective pathways and therapeutics in neurodegeneration
Dal Prà et al. Family C G-protein-coupled receptors in Alzheimer’s disease and therapeutic implications
Iascone et al. Spinal muscular atrophy: from tissue specificity to therapeutic strategies
Gao et al. Potential therapeutic applications of differentiated induced pluripotent stem cells (iPSCs) in the treatment of neurodegenerative diseases
JP7261352B2 (ja) アミロイドベータ蓄積及び／又は凝集抑制組成物及び抑制方法
Melone et al. Huntington's disease: new frontiers for molecular and cell therapy
CN113728230A (zh) 检测、预防、逆转和治疗神经系统疾病的方法
JP2024521401A (ja) 神経細胞リプログラミングのための方法及び組成物
He et al. Potential roles of Nr4a3-mediated inflammation in immunological and neurological diseases
Knorr et al. The cytokine receptor CRLF3 is a human neuroprotective EV-3 (Epo) receptor
Zhou et al. Cellular reprogramming and its potential application in Alzheimer’s disease
An et al. TRANsCre-DIONE transdifferentiates scar-forming reactive astrocytes into functional motor neurons
Tsai Therapy development for spinal muscular atrophy in SMN independent targets
Guo et al. Cryptic splicing in synaptic and membrane excitability genes links TDP-43 loss to neuronal dysfunction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250606

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260410